You searched for "vascularisation"
Topical doxycycline for corneal neovascularisation
Six eyes with corneal vascularisation were treated with 1% topical doxycycline, four times a day for three weeks. The patients were reviewed at various intervals over a period of one year. The eyes selected had neovascularisation secondary to a variety...
Late stromal rejection in DALK
This case series reported on late stromal rejections in eyes after uncomplicated deep anterior lamellar keratoplasties (DALKs). Four eyes of three patients experienced episodes of isolated stromal rejection 33 to 46 months after surgically uncomplicated DALKs and a minimum of...
Type 3 CNV and anti-VEGF
The purpose of the study was to determine the differences between aflibercept and ranibizumab in terms of their therapeutic efficacy in the treatment of Type 3 neovascularisation. The authors highlight that the dominant mechanism for Type 3 neovascularisation development is...
Comparison of treatment regimes for APROP
The authors evaluated the risk factors and treatment outcomes of various treatment options for APROP including intra-vitreal anti-VEGF injections, laser treatment and a combination of both. This was an observational study of all consecutive cases of untreated APROP from 2018-19...
Outcomes of reinjection of Ranibizumab for reactivation of retinopathy of prematurity
The authors present their data from Egypt assessing the effects of Ranibizumab reinjection for neonates with retinopathy of prematurity (ROP). Doses given were 0.25mg/0.025mL. They screened 2318 infants with 115 (5%) of infants with a mean post menstrual age (PMA)...
Treat-and-extend regimen in treatment of patients with type 3 neovascularisation
Type 3 neovascularisation, also known as retinal angiomatous proliferation is a distinct subtype of neovascular AMD characterised by intraretinal neovascularisation. This retrospective study included 17 eyes diagnosed with type 3 neovascularisation who were changed from pro-re-nata (PRN) based treatment regime...
Intravitreal ranibizumab for the treatment of myopic CNV
The authors conducted a prospective study. Sixty-four patients (65 eyes) attended the 12-month follow-up examination. The mean patient age was 47.8 years. Fifty-five patients (86.0%) were females. All patients had pathologic myopia (a spherical equivalent of more than − 6.0...A patient report of pseudoxanthoma elasticum, angioid streaks and choroidal neovascularisation
Angioid streaks (AS) on their own do not cause many problems, with the majority of patients remaining asymptomatic [1]. However, once choroidal neovascularisation (CNV) occurs, the visual prognosis of the patient rapidly declines [2]. Treatment is imperative to try and...
Progression of myopic maculopathy after treatment
The authors report on a retrospective study carried out to evaluate long-term progression of myopic maculopathy and functional outcome in eyes treated for myopic choroidal neovascularisation (CNV) and in eyes without CNV. Fifty-four myopic eyes of 30 patients were included...
ROP anti-VEGF treatment review
The purpose of this review was to consider data relating to risks and benefits of the use of anti-VEGF treatment for retinopathy of prematurity (ROP) over the past five years of 2015-2020. Ocular benefits include treatment of aggressive posterior ROP,...
FA findings in treatment-naive premature infants
This retrospective study examined fluorescein angiography (FA) images of 162 eyes of 81 treatment-naive infants with retinal vascular immaturity and persistent avascular retina (PAR) despite exceeding postmenstrual age of 60 weeks. Disc diameter (DD), optic disc-to-fovea distance (FD), the length...
